Alexandra Toohey
@Baker Bros. Advisors Lp
Latest period2024 - Q3ReportedManaged Assets$9.649BTotal holdings93
Assets growth rate23.31%Assets growth rate (2-Q avg)10.74%Continuous growth in asset value1 quarters
Portfolio positions
This chart displays the top 10 holdings in Baker Bros. Advisors Lp's 2024 - Q3 portfolio, based on their 13F SEC filing, out of a total of 93 positions.
Assets under management
The assets under management (AUM) of Baker Bros. Advisors Lp over the past 10 years (40 quarters) show continuous growth in total asset value over the last 1 quarters. As of the latest 13F SEC filing for 2024 - Q3, they manage 9.649B in assets, with a quarterly growth rate of 23.31% and a 2-quarter average growth rate of 10.74%. The portfolio is managed by Alexandra Toohey, and others.
Portfolio holdings
Investment | Portfolio % | Reported Value | Recent Activity |
---|---|---|---|
KNSAKiniksa Pharmaceuticals International, Plc
| 0.73% | $70.43M 2.818M shares@ $25.0 avg price | |
IGMSIgm Biosciences, Inc.
| 0.71% | $67.687M 4.092M shares@ $16.54 avg price | Increased 0.05% |
ARGXArgenx Se
| 0.63% | $60.661M 111,904 shares@ $542.08 avg price | |
STOKStoke Therapeutics, Inc.
| 0.56% | $53.688M 4.368M shares@ $12.29 avg price | |
IMCRImmunocore Holdings Plc
| 0.49% | $47.172M 1.515M shares@ $31.13 avg price | |
KODKodiak Sciences Inc.
| 0.47% | $45.18M 17.31M shares@ $2.62 avg price | |
SERASera Prognostics, Inc.
| 0.44% | $42.388M 5.434M shares@ $7.8 avg price | |
CRSPCrispr Therapeutics Ag
| 0.42% | $39.608M 843,075 shares@ $46.99 avg price | Increased 743.08% |
XENEXenon Pharmaceuticals Inc.
| 0.41% | $39.121M 993,679 shares@ $39.37 avg price | |
IMVTImmunovant, Inc.
| 0.37% | $34.936M 1.225M shares@ $28.51 avg price | Increased 163.69% |